Clinical Trial Update: Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating rituximab and cyclophosphamide followed by vaccine therapy in relapsed Hodgkin lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Rituximab (rituximab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-02-26